Efficacy of intravenous sotalol on ventricular arrhythmias occurring during maximal exercise stress testing.
The efficacy and safety of an intravenous dose of 40 to 100 mg sotalol was evaluated in fourteen symptomatic patients with ventricular arrhythmias occurring during maximal exercise stress testing. A statistically significant reduction in premature ventricular complexes (PVC's) occurring as singles, doublets and triplets was observed during both exercise (p less than 0.05) and recovery (p less than 0.01). Sotalol plasma levels after administration of 100 mg i.v. ranged from 3.7 to 4.75 micrograms/ml (average 4.2 micrograms/ml). The injected dose was well tolerated in all patients. Neither arrhythmogenic nor adverse effects were observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents; D001145:Arrhythmias, Cardiac / Q000503:physiopathology; D004569:Electroencephalography; D005080:Exercise Test; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D013015:Sotalol / Q000008:administration & dosage / Q000494:pharmacology*
D000889:Anti-Arrhythmia Agents; D013015:Sotalol